AMAG Pharma (AMAG) Reports Q1 Loss of $3.54/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AMAG Pharmaceuticals Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 7, 2019 7:01 AM EDTAchieved record Feraheme revenue growth and more than 50% market share for Makena auto-injector
Completed integration of Perosphere Pharmaceuticals Inc. and progressed ciraparantag clinical program
Reaffirms 2019 financial guidance
Conference call scheduled for 8:00 a.m. ET today
WALTHAM, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the first quarter ended March 31, 2019 and provided a business update.
Total revenue for the first quarter of 2019 was $75.8 million, compared with $117.4 million in the same period last year. Makena®... More
